Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis
{{output}}
Background: Third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) osimertinib is approved as first-line treatment against non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations. Herein, we perform retrospect... ...
